Cargando…

Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series

BACKGROUND: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors. CASE REPORTS: This case series presents the results of three patients with recurrent or inoperable...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernhardt, Denise, Sterzing, Florian, Adeberg, Sebastian, Herfarth, Klaus, Katayama, Sonja, Foerster, Robert, Hoerner-Rieber, Juliane, König, Laila, Debus, Juergen, Rieken, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875408/
https://www.ncbi.nlm.nih.gov/pubmed/29618938
http://dx.doi.org/10.2147/CMAR.S148395
_version_ 1783310345758048256
author Bernhardt, Denise
Sterzing, Florian
Adeberg, Sebastian
Herfarth, Klaus
Katayama, Sonja
Foerster, Robert
Hoerner-Rieber, Juliane
König, Laila
Debus, Juergen
Rieken, Stefan
author_facet Bernhardt, Denise
Sterzing, Florian
Adeberg, Sebastian
Herfarth, Klaus
Katayama, Sonja
Foerster, Robert
Hoerner-Rieber, Juliane
König, Laila
Debus, Juergen
Rieken, Stefan
author_sort Bernhardt, Denise
collection PubMed
description BACKGROUND: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors. CASE REPORTS: This case series presents the results of three patients with recurrent or inoperable pelvic ACC treated with intensity-modulated radiotherapy (IMRT) plus carbon ion (C12) boost. Patients received C12 therapy at a dose of 3 Gray equivalents (GyE) (relative biological effectiveness [RBE]) per fraction up to 24 GyE RBE, followed by 50 GyE of photon IMRT in 25 fractions. CONCLUSION: IMRT plus C12 ion boost as a definitive or adjuvant treatment for pelvic ACCs seems to be a promising therapeutic option. No unexpected toxicity was detected and the observed toxicity remained consistently low. The initial treatment response is promising and similar to that experienced for head and neck ACCs.
format Online
Article
Text
id pubmed-5875408
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58754082018-04-04 Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series Bernhardt, Denise Sterzing, Florian Adeberg, Sebastian Herfarth, Klaus Katayama, Sonja Foerster, Robert Hoerner-Rieber, Juliane König, Laila Debus, Juergen Rieken, Stefan Cancer Manag Res Case Series BACKGROUND: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors. CASE REPORTS: This case series presents the results of three patients with recurrent or inoperable pelvic ACC treated with intensity-modulated radiotherapy (IMRT) plus carbon ion (C12) boost. Patients received C12 therapy at a dose of 3 Gray equivalents (GyE) (relative biological effectiveness [RBE]) per fraction up to 24 GyE RBE, followed by 50 GyE of photon IMRT in 25 fractions. CONCLUSION: IMRT plus C12 ion boost as a definitive or adjuvant treatment for pelvic ACCs seems to be a promising therapeutic option. No unexpected toxicity was detected and the observed toxicity remained consistently low. The initial treatment response is promising and similar to that experienced for head and neck ACCs. Dove Medical Press 2018-03-26 /pmc/articles/PMC5875408/ /pubmed/29618938 http://dx.doi.org/10.2147/CMAR.S148395 Text en © 2018 Bernhardt et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Series
Bernhardt, Denise
Sterzing, Florian
Adeberg, Sebastian
Herfarth, Klaus
Katayama, Sonja
Foerster, Robert
Hoerner-Rieber, Juliane
König, Laila
Debus, Juergen
Rieken, Stefan
Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
title Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
title_full Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
title_fullStr Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
title_full_unstemmed Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
title_short Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
title_sort bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875408/
https://www.ncbi.nlm.nih.gov/pubmed/29618938
http://dx.doi.org/10.2147/CMAR.S148395
work_keys_str_mv AT bernhardtdenise bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT sterzingflorian bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT adebergsebastian bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT herfarthklaus bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT katayamasonja bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT foersterrobert bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT hoernerrieberjuliane bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT koniglaila bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT debusjuergen bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries
AT riekenstefan bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries